Bladder Cancer

Cancer of the bladder is the fourth most common malignancy among males and the tenth most common malignancy among females. Each year in the United States, over 50,000 people develop bladder cancer. Effective treatment can save many lives.

Developing a personalized treatment plan is a team effort, with many different specialists working together to provide the best possible care for each patient. The pathologist’s role is to determine the correct diagnosis by examining biopsy slides provided by either a referring physician or the patient. This diagnosis is then shared with oncologists and surgeons, who will work with patients to devise an appropriate treatment plan. But it all hinges on an accurate initial diagnosis. That’s why we’re here.

Jonathan Epstein, M.D.

Contact Us

Getting a second opinion on your pathology diagnosis can clarify or even change a diagnosis. This can affect prognosis as well as therapy, and adds important data that contributes to a larger cause: making sure every diagnosis of bladder cancer, everywhere, is as accurate as possible.

Pathology slide

Your Results

Your Pathologist will use slides to help determine the following about a tumor:

  • Whether it is benign or malignant
  • Whether there is invasion and the depth of invasion
  • The presence of morphologic variants of urothelial carcinoma

Dr. Andres Matoso and Resident

How We Can Help

The Bladder Pathology Service of Johns Hopkins Hospital provides expert second opinions within 24 hours of sample receipt. We also provide resources for current clinical trials that are testing new treatment methods against current standards of care.

Andres Matoso and Jonathan Epstein

Our Expertise

Diagnosing and treating bladder cancer is truly a multidisciplinary team effort. The Bladder Pathology Service is one integral part of the comprehensive, patient-centered team approach to bladder cancer at Johns Hopkins.


Bladder cancer is the 4th most common cancer in men


present with superficial disease (stage 0-1) but this cancer has high recurrence rate


Bladder cancer is the fifth most common cancer in the U.S.